Similar articles

• Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.

  Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y. Iwata S, et al. Mod Rheumatol. 2011 Apr;21(2):184-91. doi: 10.1007/s10165-010-0370-y. Epub 2010 Nov 5. Mod Rheumatol. 2011. PMID: 21052764
• Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.

  Jalili A, Kinaciyan T, Barisani T, Peck-Radosavljevic M, Stingl G, Geusau A, Wöhrl S. Jalili A, et al. Iran J Immunol. 2009 Mar;6(1):55-8. Iran J Immunol. 2009. PMID: 19293479 No abstract available.
• [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].

  van Laar JA, Jamnitski A, Baarsma GS, van Daele PL, van Hagen PM. van Laar JA, et al. Ned Tijdschr Geneeskd. 2006 Apr 1;150(13):705-9. Ned Tijdschr Geneeskd. 2006. PMID: 16623340 Dutch.
• Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.

  Park J, Cheon JH. Park J, et al. Gut Liver. 2018 Nov 15;12(6):623-632. doi: 10.5009/gnl17462. Gut Liver. 2018. PMID: 29788675 Free PMC article. Review.
• Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

  Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H. Sfikakis PP, et al. Rheumatology (Oxford). 2007 May;46(5):736-41. doi: 10.1093/rheumatology/kem034. Epub 2007 Apr 2. Rheumatology (Oxford). 2007. PMID: 17403712 Review. No abstract available.